Gene therapies are a hard sell. Bluebird hopes to win in Europe- STAT

Gene therapies are a hard sell. Bluebird hopes to win in Europe- STAT

STAT Plus: Gene therapies are a hard sell. Bluebird hopes to do better in Europe

By ADAM FEUERSTEIN

RUBY WALLAU FOR STAT

Bluebird Bio is nearing European approval of its first gene therapy for a rare blood disorder. It hopes to move faster there than Novartis.

READ MORE